Company / R&D Expense
Progyny R&D Expense History
FY2025-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$9.5M
FY2025
5-year range
$9.5M / $9.5M
FY2025-FY2025
Trend
-
vs FY2024
Sector context
#100 of 105
Health Care
What the data says
Among 105 Health Care companies, Progyny is in the bottom 5% for r&d expense.
Based on SEC 10-K filings.
$10M in FY2025.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 5% in Health CareTop 95% of 105This company $9.5M Sector average $284.2M
▼
-96.7% below sector average
Company context
Key Data Points
- Altman Z-Score 3.62 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.5M | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026